Brazil does not authorize Russian vaccine Sputnik V and Russia speaks of a 'political' decision

04/27/2021 7:49 AM

• Clarín.com

• World

Updated 04/27/2021 7:49 AM

The manufacturers of the Russian vaccine against the coronavirus Sputnik V denounced on Tuesday the decision of the Brazilian government, according to them "political",

not to authorize the importation of the drug.

"The delays by Anvisa (the Brazilian health regulatory agency) in the approval of Sputnik V

are unfortunately of a political nature

and have nothing to do with access to information or scientific aspects," reads the Twitter account of the Russian vaccine.

"The US Health Ministry, in its 2020 annual report several months ago, publicly stated that the US health attaché

'had convinced Brazil to reject the Russian vaccine,

'" they add.

The Brazilian health regulator on Monday denied a request from several states in the country to import the Sputnik V vaccine,

considering that it lacks technical data to verify its safety and efficacy.

The five directors of Anvisa followed the recommendation of the technical area of ​​the agency, which

pointed out several "uncertainties" in relation to the safety and efficacy of the immunizer

, which has not yet been approved by the European Medicines Agency (EMA) or the FDA (Administration Federal Food and Drug Administration) of the United States.

"We will continue with our contacts. If information is missing, it will be provided. There should be no doubt about it," added Kremlin spokesman Dmitri Peskov this Tuesday in his appearance before the press.

The Bolsonaro government maintains a questionable administration of the pandemic.

Photo: Bloomberg.

The president of Anvisa,

Antonio Barra Torres

, indicated that the Russian manufacturer did not deliver the "complete technical report" of the immunizer, which lacks approval in Japan, Europe and the United States, countries that in this type of situation would automatically endorse the approval of any medicine in Brazil.

The Sputnik V vaccine is administered in countries other than Russia, such as

Mexico, Argentina, or Venezuela

.

According to the Russian Gamaleya institute, which created the vaccine, it has been licensed in more than 60 countries.

In February, the prestigious medical journal

The Lancet

, reported that its effectiveness was 91.6%, a figure that dispelled doubts about its reliability.

In an attempt to speed up their vaccination plans, a dozen states in the north and northeast of Brazil signed contracts with the Russian Sovereign Fund (RDIF), which financed the development of Sputnik V, to acquire more than 30 million doses.

The Brazilian federal government also acquired another 10 million.

With information from agencies.

JPE

Look also

Now Russia assures that the interval between the two doses of the Sputnik V vaccine can be three months

AstraZeneca vaccine: Liomont laboratory explained the delays